CD8A and cancer: We acknowledge that it would be very useful to perform comparative TAME analyses between our WT1A and WT1B antigens with other published cancer antigens, such as WT137-45 from Schmied et al.'s and MART126-35 from Alanio et al.'s studies.28, 37 Nevertheless, these data on numbers of naive CD8+ T cells directed against WT1A and WT1B can be used for the future assessments of any cancer vaccine, which utilizes WT1A and/or WT1B components.